Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trehalose-containing cell wall glycolipids, including trehalose monomycolate (TMM) and trehalose dimycolate (TDM), are essential structural and virulence components of the Mycobacterium abscessus cell envelope (Belardinelli et al., 2016, ACS Infect Dis). These molecules constitute a significant portion of the mycobacterial outer membrane, providing a dense, hydrophobic barrier that contributes to the organism's high level of intrinsic resistance to many antibiotics (Nessar et al., 2012, J Antimicrob Chemother). TDM, also known as cord factor, is particularly significant for its role in modulating host immune responses, including the inhibition of phagosome maturation and the induction of granulomatous inflammation (Hunter et al., 2006, Tuberculosis). In M. abscessus, the presence of glycopeptidolipids (GPLs) on the cell surface dictates colony morphology; the transition from a smooth to a rough phenotype, characterized by the loss of GPLs, is associated with increased virulence and biofilm-mediated persistence (Medjahed et al., 2010, BMC Microbiol). Because these glycolipids are vital for bacterial viability, the transport protein MmpL3, which translocates TMM across the inner membrane, has become a major target for novel drug development (Grzegorzewicz et al., 2012, Nat Chem Biol). Inhibiting the assembly or transport of these trehalose-based molecules disrupts the cell wall, leading to bacterial lysis and enhanced susceptibility to other therapeutic agents (Tahlan et al., 2012, Antimicrob Agents Chemother).
Inhibition of MmpL3-mediated transport of trehalose monomycolate (TMM) to the mycomembrane, preventing the assembly of the mycolic acid layer and disrupting cell wall integrity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trehalose-containing cell wall glycolipids (TCGs).